Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ototoxicity × Dexamethasone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 672 Precursor Cell Lymphoblastic Leukemia-Lymphoma 144 Recurrence 107 Neoplasms, Plasma Cell 98 Leukemia 78 Lymphoma 74 Neoplasms 70 Vomiting 47 Burkitt Lymphoma 44 Lymphoma, Non-Hodgkin 41 Immunoglobulin Light-chain Amyloidosis 41 Lymphoma, Large B-Cell, Diffuse 33 Lymphoma, Mantle-Cell 31 Nausea 30 Prostatic Neoplasms 29 Lymphoma, Follicular 27 Waldenstrom Macroglobulinemia 26 Neoplasm Metastasis 23 Breast Neoplasms 23 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22 Leukemia, Myeloid, Acute 22 Hodgkin Disease 22 Leukemia, Lymphocytic, Chronic, B-Cell 21 Carcinoma, Non-Small-Cell Lung 21 Lung Neoplasms 19 Amyloidosis 16 Lymphoma, Extranodal NK-T-Cell 14 Lymphoma, B-Cell, Marginal Zone 14 Leukemia, Biphenotypic, Acute 14 Colorectal Neoplasms 13

Interventions

sodium thiosulfate 3 Cisplatin 3 tempol 1 ebselen 1 Vorinostat 1 Thioctic Acid 1 Surveys and Questionnaires 1 Sodium Chloride 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Radiotherapy 1 Radiosurgery 1 Pantoprazole 1 Methotrexate 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Hyaluronic Acid 1 Hearing Tests 1 Drug Therapy 1 Dexamethasone 1 Chemotherapy, Adjuvant 1 Chemoradiotherapy 1 Audiometry 1 Atorvastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡